Biomea Fusion (BMEA) risk factors, FY2025 10-K

Other

1. 01Risks Related to Our Limited Operating History, Business, Financial Condition, Results of Operations, and Need for Additional Capital100% rewritten
2. 02We have limited experience as a company in conducting clinical trials and have not successfully completed the clinical development of any product candidates to date. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history
3. 03We have incurred significant net losses in each period since our inception, and we expect to incur significant net losses for the foreseeable future31% rewritten
4. 04operate as a public company
5. 05We have not generated any revenue from our product candidates and may never generate revenue or be profitable. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery and development of our product candidates
6. 06attracting, hiring, and retaining qualified personnel
7. 07We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs or future commercialization efforts
8. 08the impact of adverse global economic conditions on our business, which may exacerbate the magnitude of the factors discussed above
9. 09There is substantial doubt about our ability to continue as a going concern
10. 10Based on our current operating plan, we will not be able to continue as a going concern over the next twelve months unless we raise additional capital by other means. These factors raise substantial doubt about our ability to continue as a going concern78% rewritten
11. 11respond to competitive pressures36% rewritten
12. 12Potential or actual breach of financial covenants in any credit agreements or credit arrangements

Risks Related to Product Development

1. 13maintaining a continued acceptable safety profile of our products following approval
2. 14third parties being unwilling or unable to satisfy their contractual obligations to us
3. 15We face risks related to global health emergencies such as a pandemic, epidemic, or outbreak of an infectious disease, which could materially adversely impact our business, results of operations, and financial condition, including our preclinical studies and clinical trialsNew
4. 16If we experience delays or difficulties in the enrollment and/or retention of eligible participants in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented
5. 17proximity and availability of clinical trial sites for prospective participants
6. 18The market opportunities for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate24% rewritten
7. 19We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do85% rewritten
8. 20Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs22% rewritten
9. 21Interim, “top-line”, and preliminary data from our clinical trials that we announce or publish from time to time may change as more participants data become available and are subject to audit and verification procedures that could result in material changes in the final data
10. 22Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, and others in the medical community
11. 23If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, or others in the medical community, we will not be able to generate significant revenue
12. 24Even if any products we develop achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete
13. 25If product liability lawsuits are brought against us, we may incur substantial liabilities, which may not be sufficiently covered by insurance, and may be required to limit commercialization of our product candidates
14. 26a decline in our share price
15. 27We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators

Risks Related to Regulatory Process and Other Legal Compliance Matters

1. 28the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
2. 29Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval
3. 30We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
4. 31Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions66% rewritten
5. 32Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operationsNew
6. 33injunctions or the imposition of civil or criminal penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
7. 34Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
8. 35the availability of capital
9. 36The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
10. 37Our employees, independent contractors, consultants, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
11. 38Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties62% rewritten
12. 39Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing
13. 40Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates

Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business

1. 41We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy25% rewritten
2. 42As of December 31, 2025, we had 41 full-time employees, including 27 employees engaged in research and development activitiesNew
3. 43improving our operational, financial and management controls, reporting systems and procedures
4. 44Business disruptions could materially adversely affect our future revenue and financial condition and increase our costs and expenses
5. 45Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited
6. 46Changes in tax law may adversely affect us or our investors48% rewritten

Risks Related to Reliance on Third Parties

1. 47our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or man-made disasters; and
2. 48We currently, and may in the future, depend on single-source suppliers for some of the ingredients, components and materials used in, and the manufacturing processes required to develop, our product candidates
3. 49If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages
4. 50We may, in the future, form or seek collaborations or strategic alliances or enter into licensing arrangements, and we may not realize the benefits of such collaborations, alliances or licensing arrangements
5. 51collaborators may own or co-own intellectual property covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property
6. 52If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
7. 53our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs

Risks Related to Intellectual Property

1. 54If any of our patents are found to be invalid or unenforceable, or if we are otherwise unable to adequately protect our rights, it could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates
2. 55Our success depends in part on our ability to protect our intellectual property rights. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world
3. 56Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
4. 57Any issued patents we may own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO
5. 58We may become involved in lawsuits or litigation at the USPTO to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful60% rewritten
6. 59Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our technology, products and product candidates
7. 60We may be subject to claims challenging the inventorship of our patents and other intellectual property
8. 61If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
9. 62Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline
10. 63We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers
11. 64If we fail to comply with our obligations in any future agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business
12. 65the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
13. 66Intellectual property rights do not necessarily address all potential threats

Risks Related to Our Common Stock

1. 67The price of our stock has been and is likely to continue to be volatile, and you may not be able to resell shares of our common stock at or above the price you paid
2. 68The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock
3. 69Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
4. 70A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly
5. 71Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or upon the exercise of outstanding warrants, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall43% rewritten
6. 72Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities75% rewritten
7. 73Our management and directors own our stock and may be able to exert influence over matters subject to stockholder approval41% rewritten
8. 74We do not intend to pay dividends on our capital stock, so any returns will be limited to the value of our stock
9. 75Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock
10. 76require a super-majority vote of stockholders to amend some provisions described above
11. 77Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
12. 78we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents
13. 79We may be subject to securities litigation, which is expensive and could divert management attention
14. 80Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance91% rewritten
15. 81the changing and volatile global economic and political environment
16. 82We will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives
17. 83Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies
18. 84Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
19. 85Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations
20. 86We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors
21. 87exemptions from the requirements of holding non-binding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved
22. 88Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations41% rewritten
23. 89Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price37% rewritten
24. 90If our security measures are compromised, or the security, confidentiality, integrity, or availability of our information technology, software, services, communications or data is compromised, limited or fails, this could result in a material adverse impact
25. 91If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
26. 92If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
27. 93Our business could be negatively impacted by corporate citizenship and environmental, social and corporate governance (ESG) matters and/or our reporting of such matters
28. 94Geopolitical events and conditions could adversely affect our business, financial condition and operating results27% rewritten
29. 95The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
30. 96ESG matters may impact our business and reputationNew